FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer.

Martina CatalanoRaffaele ConcaRoberto PetrioliMonica RamelloGiandomenico Roviello

Published in: Cancer management and research (2020)

Our results seem to support the use of fluoropyrimidine-based second-line therapy for patients with metastatic pancreatic cancer, confirming the effectiveness and safety, to a greater extent with FOLFIRI regimen, after progression to the Gem-NabP.

Keyphrases

metastatic colorectal cancer
wild type
advanced non small cell lung cancer
locally advanced
stem cells
mesenchymal stem cells
radiation therapy
chemotherapy induced